By Karen Roman
Lisata Therapeutics, Inc. (Nasdaq: LSTA) said it started a global product license agreement with Catalent, Inc., enabling the latter to include Lisata’s certepetide into antibody-drug conjugates (ADCs) developed using Catalent’s SMARTag technology platform.
The partnership is a validation of certepetide’s versatility and positions Lisata’s technology within a leading ADC platform, the company stated.
Catalent acquires non-exclusive rights to develop and commercialize products with certepetide and its analogs, Lisata said.
“This collaboration underscores our mutual belief in certepetide’s broad potential and is another significant step forward in Lisata’s mission to bring transformative therapies to patients,” said Kristen K. Buck, M.D., Lisata’s Executive Vice President of Research and Development and Chief Medical Officer.
READ MORE
Updated Preliminary Agenda: 5th Palm Beach CorpGov Forum Nov 5-6
Never Miss our Weekly Highlights HERE
